or Try an Advanced Search...

    Technical Analysis for MBRX - Moleculin Biotech, Inc.

    Grade Last Price % Change Price Change
    C 2.67 2.10% 0.06
    MBRX closed up 2.1 percent on Wednesday, November 20, 2024, on 71 percent of normal volume.
    0 Watchers
    Watchlist Portfolio

    Trend Table & Recent EOD Trading Signals

    ADX Long Term Intermediate Term Short Term
    Weak or Absent Down Up Up
    Historical MBRX trend table...
    Date Alert Name Type % Chg
    Gapped Up Strength 0.00%
    50 DMA Support Bullish 2.10%
    Crossed Above 20 DMA Bullish 2.10%
    Pocket Pivot Bullish Swing Setup 2.10%
    Calm After Storm Range Contraction 2.10%
    Inside Day Range Contraction 2.10%
    Gapped Up Strength 2.10%
    Fell Below 20 DMA Bearish 5.95%
    50 DMA Support Bullish 5.95%
    Upper Bollinger Band Touch Strength 5.95%
    Older End-of-Day Signals for MBRX ...

       Recent Intraday Alerts

    Alert Time
    Rose Above Previous Day's High about 21 hours ago
    Up 5% about 21 hours ago
    Up 3% about 21 hours ago
    Up 2% about 21 hours ago
    Up 1% about 21 hours ago
    View Earlier Intraday Alerts

    Free Daily (Stock) Chart Reading

    Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
    Read My Charts!
    Configure default chart indicators
    MBRX Chart by TradingView
    Basic chart:

    Profile

    Moleculin Biotech, Inc., a preclinical and clinical-stage pharmaceutical company, focuses on the development of anti-cancer drug candidates. Its lead drug candidate is liposomal Annamycin, an anthracycline intended for the treatment of relapsed or refractory acute myeloid leukemia. The company also develops other drugs, including WP1066 Portfolio, a portfolio of small molecules targeting the modulation of transcription factors involved in cancer; and WP1122 Portfolio, a suite of molecules targeting the metabolic processes involved in cancer and glioblastoma. Moleculin Biotech, Inc. was founded in 2015 and is headquartered in Houston, Texas.
    Classification
    Sector: Healthcare
    Industry: Biotechnology
    Keywords: Medicine Cancer Pharmaceutical Oncology Acute Myeloid Leukemia Chemotherapy Antineoplastic Drugs Blastoma Glioblastoma Stage Pharmaceutical Transcription Transcription Factors Refractory Acute Myeloid Leukemia Transcription Factor Treatment Of Relapsed Or Refractory Acute Myeloid Leukemia

    Is MBRX a Buy, Sell or Hold?

    Indicator Bull Case Neutral / Hold Bear Case
    50 DMA
    200 DMA
    ADX Trend
    Oversold / Overbought
    Relative Strength
    Counts: 1 bullish, 1 bearish and 3 neutral indicators. You may wish to incorporate that into your trading strategies.

    Recent News

    Date Title
    Nov 14 Moleculin accelerates data readout for its late-stage leukemia treatment to H2 2025
    Nov 14 Moleculin Accelerates Planned Unblinded Data Readout for MIRACLE Phase 3 R/R Acute Myeloid Leukemia (AML) Pivotal Trial to H2 2025
    Nov 13 Moleculin Biotech Reports Financial Highlights and Future Plans
    Nov 12 Moleculin Receives Institutional Review Board Approval for MIRACLE Phase 3 Pivotal Trial of Annamycin in Combination with Cytarabine for the Treatment of R/R Acute Myeloid Leukemia (AML)
    Nov 12 Q3 2024 Moleculin Biotech Inc Earnings Call
    Nov 11 Moleculin Biotech, Inc. (MBRX) Q3 2024 Earnings Call Transcript
    Nov 11 Moleculin Biotech GAAP EPS of -$2.85
    Nov 11 Moleculin Reports Third Quarter 2024 Financial Results and Provides Corporate Update
    Nov 5 Moleculin to Report Third Quarter 2024 Financial Results on November 8, 2024 and Host Conference Call and Webcast
    Nov 4 Moleculin Appoints Leading Expert in Pancreatic Cancer to its Scientific Advisory Board to Support Development of Annamycin
    See more MBRX news...

    Comments

    View full discussion...

    Indicators

    Indicator Value
    52 Week High 15.75
    52 Week Low 2.115
    Average Volume 47,306
    200-Day Moving Average 4.28
    50-Day Moving Average 2.53
    20-Day Moving Average 2.56
    10-Day Moving Average 2.62
    Average True Range 0.26
    RSI (14) 52.83
    ADX 21.98
    +DI 26.39
    -DI 12.62
    Chandelier Exit (Long, 3 ATRs) 2.55
    Chandelier Exit (Short, 3 ATRs) 3.07
    Upper Bollinger Bands 2.88
    Lower Bollinger Band 2.25
    Percent B (%b) 0.67
    BandWidth 24.55
    MACD Line 0.04
    MACD Signal Line 0.02
    MACD Histogram 0.0155
    Fundamentals Value
    Market Cap 89.21 Million
    Num Shares 33.4 Million
    EPS -0.89
    Price-to-Earnings (P/E) Ratio -3.00
    Price-to-Sales 0.00
    Price-to-Book 0.48
    PEG Ratio 0.00
    Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
    Resistance 4 (R4) 3.02
    Resistance 3 (R3) 3.03 2.94 2.96
    Resistance 2 (R2) 2.94 2.85 2.93 2.94
    Resistance 1 (R1) 2.80 2.79 2.76 2.79 2.92
    Pivot Point 2.71 2.71 2.68 2.70 2.71
    Support 1 (S1) 2.57 2.62 2.53 2.56 2.42
    Support 2 (S2) 2.48 2.56 2.47 2.40
    Support 3 (S3) 2.34 2.48 2.38
    Support 4 (S4) 2.33